Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combined medicine capable of improving sensibility of tumors to paclitaxel

A paclitaxel, sensitive technology, applied in the field of anticancer drugs, can solve the problem of low toxicity

Inactive Publication Date: 2013-08-07
XIAMEN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Praziquantel is a high-efficiency broad-spectrum anti-parasitic drug, which has been used clinically for many years to treat parasites, especially for schistosomiasis, clonorchis sinensis and paragonimus. The adults and larvae of the worm, ginger and various tapeworms all have significant insecticidal effects, and have low toxicity and are easy to use (3.GonnertR, Andrews P: Praziquantel, a new board-spectrum antichistosomal agent. ZParasitenkd 1977; 52: 129-150; 4.Grover JK, Vats V, Uppal G, Yadav S: Anthelmintics: a review.Trop Gastroenterol 2001; 22:180-189), there is no report about praziquantel involved in anti-tumor therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combined medicine capable of improving sensibility of tumors to paclitaxel
  • Combined medicine capable of improving sensibility of tumors to paclitaxel
  • Combined medicine capable of improving sensibility of tumors to paclitaxel

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Embodiment 1, detecting the sensitivity of different tumor cells to paclitaxel

[0017] The sensitivity of different tumor cell lines to paclitaxel was detected by MTT method. Human cervical cancer cells HeLa, prostate cancer cells PC-3, colon cancer cells SW620, HT29, HCT-116, DLD-1, lung cancer cells Ltep-a-2, Spc-a-1, H460, H1299, A549, breast cancer cells Cancer cells MDA-MB-231, ZR-7530, and Bcap37 were inoculated into 96-well plates at the number of 5000-7000 cells per well. After 12-16 hours, they were treated with 0-200 nM paclitaxel for 48 hours, and then the culture medium was sucked off. Add 80-120 μl of cell culture medium containing 0.5 mg / ml MTT to the well, react at 37°C for 2-4 hours, remove the cell culture medium, and add 100 μl of dimethyl sulfoxide (DMSO) to each well to dissolve the formed in the previous step. Formazan was crystallized, and the OD570 reading was detected with a microplate reader. The growth inhibition rate of paclitaxel to cells ...

Embodiment 2

[0021] Example 2. Detecting the effect of paclitaxel alone or praziquantel alone and their combined use on the survival rate of ZR-7530, HeLa, Spc-a-1, Ltep-a-2, Bcap-37 and other tumor cell lines influences

[0022] Cells such as breast cancer cells ZR-7530 and Bcap-37, human cervical cancer cells HeLa, lung cancer cells Spc-a-1 and Ltep-a-2 were seeded on a 96-well plate at a density of 5000-7000 cells per well, After 12 to 16 hours, add praziquantel and paclitaxel alone or in combination. Use different ratios of praziquantel and paclitaxel to treat different tumor cell lines. : 1 (mass ratio), the treatment time is 48h; when processing Bcap-37 and Spc-a-1 cells, the ratio of praziquantel and paclitaxel is 2200: 1 (mass ratio), and the treatment time is 48h; - For a-2 cells, the ratio of praziquantel and paclitaxel is 2200:1 (mass ratio), and the treatment time is 60 h. Then obtain the OD570 reading value according to the MTT method described in Example 1, and then calcul...

Embodiment 3

[0024] Example 3. Comparison of the effect of paclitaxel alone and its combination with praziquantel on the survival rate of colon cancer cell DLD-1 and lung cancer cell H1299

[0025]Colon cancer cells DLD-1 and lung cancer cells H1299, which are not sensitive to paclitaxel, were seeded on 96-well plates at a density of 5000-7000 cells per well. After 12-16 hours, paclitaxel at a concentration of 0-80 nM, or 20 μM Quinone, or 20μM praziquantel combined with 0-80nM paclitaxel, the treatment time is 24-48h. Then the OD570 reading was obtained according to the MTT method described in Example 1, and then calculated according to the formula in Example 2 to obtain the survival rate of the cells under different treatment conditions.

[0026] image 3 and Figure 4 The cell survival curves of colon cancer cells DLD-1 and lung cancer cells H1299 were treated with paclitaxel alone or paclitaxel and praziquantel combined, respectively. image 3 and 4 It can be seen that when the con...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a combined medicine capable of improving the sensibility of tumors to paclitaxel, and relates to an antitumor medicine. The combined medicine comprises praziquantel and the paclitaxel, wherein a mass ratio of the praziquantel to the paclitaxel is (180-2,200):1. The combined medicine can improve the sensibility of the tumors to the paclitaxel and the killing capacity of the paclitaxel on the tumors effectively, promote the apoptosis of tumor cells greatly, improve the sensibility of the tumors which are insensitive or resistant to the paclitaxel to the paclitaxel effectively and reduce the resistance of the tumor cells to the paclitaxel greatly.

Description

technical field [0001] The invention relates to an antitumor drug, in particular to a novel combination medicine which can improve the sensitivity of tumors to paclitaxel (Taxol) in tumor treatment. Background technique [0002] Paclitaxel (Taxol) is a drug that can block the function of microtubules in cells and cause cell death. It has been widely used clinically in the treatment of solid tumors such as breast cancer, ovarian cancer, and non-small cell lung cancer (1.Jordan MA , Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4: 253-265). However, due to various reasons, such as p-glycoprotein (P-Glygoprotein) overexpression, tubulin mutation and other reasons, the drug resistance of tumor patients to paclitaxel has become more and more prominent, which has become a major obstacle to the treatment of tumor patients; and, Paclitaxel has a wide range of clinical side effects, mainly including allergic reactions, neurotoxicity, and hematopoietic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4985A61P35/00A61K31/337
Inventor 李晓彤吴振华卢明科
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com